U.S. Markets closed

United Therapeutics Corporation (UTHR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
183.27-1.30 (-0.70%)
At close: 4:00PM EDT
183.27 0.00 (0.00%)
After hours: 04:46PM EDT

United Therapeutics Corporation

1040 Spring Street
Silver Spring, MD 20910
United States
301 608 9292
http://www.unither.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees950

Key Executives

NameTitlePayExercisedYear Born
Dr. Martine A. RothblattFounder, Chairman & CEO3.24M20.56M1955
Mr. Michael I. BenkowitzPres & COO1.96M1.99M1972
Mr. James C. EdgemondCFO & Treasurer1.42MN/A1968
Mr. Paul A. MahonExec. VP, Gen. Counsel & Corp. Sec.1.67M1.04M1964
Mr. Dewey Steadman C.F.A., CFAHead of Investor RelationsN/AN/AN/A
Ms. Holly HobsonAssociate VP of HRN/AN/AN/A
Kevin T. GraySr. VP of Strategic Operations & LogisticsN/AN/AN/A
Mr. Patrick PoissonExec. VP of Technical OperationsN/AN/A1968
Mr. Gil GoldenSr. VP & Chief Medical OfficerN/AN/AN/A
Leigh PetersonVP of Product Devel.N/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Corporate Governance

United Therapeutics Corporation’s ISS Governance QualityScore as of July 1, 2021 is 3. The pillar scores are Audit: 5; Board: 2; Shareholder Rights: 3; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.